Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Public ClinicalTrials.gov record NCT00203021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.
Study identification
- NCT ID
- NCT00203021
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 1994
- Primary completion
- Feb 27, 2018
- Completion
- Feb 27, 2018
- Last update posted
- Feb 17, 2020
1994 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 009 | Los Angeles | California | 90033 | — |
| Teva Investigational Site 004 | Los Angeles | California | 90095-7077 | — |
| Teva Investigational Site 008 | New Haven | Connecticut | 06520-8018 | — |
| Teva Investigational Site 005 | Baltimore | Maryland | 21201 | — |
| Teva Investigational Site 003 | Detroit | Michigan | 48201 | — |
| Teva Investigational Site 002 | Albuquerque | New Mexico | 87131 | — |
| Teva Investigational Site 007 | Rochester | New York | 14642 | — |
| Teva Investigational Site 001 | Philadelphia | Pennsylvania | 19104 | — |
| Teva Investigational Site 010 | Houston | Texas | 77030 | — |
| Teva Investigational Site 006 | Salt Lake City | Utah | 84148 | — |
| Teva Investigational Site 011 | Madison | Wisconsin | 53719 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00203021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2020 · Synced Sep 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00203021 live on ClinicalTrials.gov.